Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
HER2 Inhibitors Market Size And Revenue Outlook Through 2030
The her2 inhibitors market size has shown robust growth over recent years. Its expansion is anticipated to continue, rising from $9.64 billion in 2025 to $10.6 billion in 2026, achieving a compound annual growth rate (CAGR) of 9.9%. Historically, this market’s growth can be linked to the initial approval of her2-targeted therapies, an increase in breast cancer incidence, enhancements in her2 diagnostic testing, positive clinical trial outcomes, and the increasing adoption of targeted oncology treatments.
The market for her2 inhibitors is anticipated to experience substantial expansion in the coming years. Its value is projected to reach $14.85 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 8.8%. This anticipated expansion over the forecast period is fueled by several factors, including enhanced identification of her2-low patients, the broadening pipeline of new her2 inhibitors, a surge in the adoption of combination therapies, wider application in metastatic and adjuvant treatment scenarios, and increased expenditure in oncology healthcare. Key trends expected during this period involve the proliferation of her2-targeted combination treatments, a growing uptake of her2 inhibitors for early-stage cancers, heightened attention on treating her2-low breast cancer, advancements in next-generation antibody-drug conjugates, and more refined patient stratification alongside improved biomarker testing.
Get A Free Sample Report With In-Depth Market Insights:
HER2 Inhibitors Market Growth Drivers: What’s Behind The Acceleration?
Governmental efforts to improve breast cancer care and treatment are anticipated to propel the growth of the HER2 inhibitors market going forward. These government initiatives, aimed at enhancing breast cancer care and treatment, encompass policies, funding, and programs implemented to improve the accessibility, affordability, and quality of care for individuals diagnosed with breast cancer. Through subsidized programs and research funding, government initiatives have broadened access to HER2 inhibitors, a breast cancer treatment, thereby advancing patient care and outcomes. For instance, in February 2023, the World Health Organization, a Switzerland-based intergovernmental organization, released a new Global Breast Cancer Initiative Framework. This framework provides a roadmap to achieve targets aimed at saving 2.5 million lives from breast cancer by 2040. Therefore, government initiatives to improve breast cancer care and treatment are a significant driver for the growth of the HER2 inhibitors market.
HER2 Inhibitors Market Segment Performance And Emerging Opportunities
The her2 inhibitors market covered in this report is segmented –
1) By Treatment: Monotherapy, Combination Therapy
2) By Application: Squamous Cell Carcinoma, Adenocarcinoma, Large Cell Carcinoma, Breast Cancer, Other Applications
3) By End User: Hospitals, Clinics, Other End Users
Subsegments:
1) By Monotherapy: Single-Agent HER2 Inhibitors, Targeted HER2 Therapies
2) By Combination Therapy: HER2 Inhibitors Combined With Chemotherapy, HER2 Inhibitors Combined With Targeted Therapies, HER2 Inhibitors Combined With Hormonal Therapies
HER2 Inhibitors Market Trends: What’s Defining The Industry’s Next Phase?
Leading companies in the HER2 inhibitor market are concentrating on developing therapies for pre-treated HR+/HER2-metastatic breast cancer to achieve a competitive edge. HR+/HER2-metastatic breast cancer is a subset of metastatic breast cancer defined by the existence of hormone receptors (HR+). For example, in February 2023, Gilead Sciences, Inc., a US-based biopharmaceutical company, received U.S. FDA approval for Trodelvy (Sacituzumab govitecan-hziy) to address adults with unresectable locally advanced or metastatic HR-positive, HER2-negative breast cancer, following prior endocrine-based treatment and two additional systemic therapies in the metastatic setting.
HER2 Inhibitors Market Key Players: Which Companies Lead Industry Competition?
Major companies operating in the her2 inhibitors market are Pfizer Inc., Johnson & Johnson Services Inc., F Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca plc, Takeda Pharmaceutical Company Limited, Eli Lilly International Corp., C.H. Boehringer Sohn AG & Co. KG, Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Company Limited, Ipsen SA, the Pierre Fabre Group, Biocon Biopharmaceuticals Pvt. Ltd., Innovent Biologics Inc., Seattle Genetics Inc., Zymeworks Inc., Puma Biotechnology Inc., MacroGenics Inc., Mersana Therapeutics Inc., Cellestia Biotech AG
View The Full HER2 Inhibitors Market Report:
HER2 Inhibitors Market Regional Analysis And Leading Geography
North America was the largest region in the HER2 inhibitors market in 2025. Middle East is expected to be the fastest-growing region in the HER2 inhibitors market report during the forecast period. The regions covered in the her2 inhibitors market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
